Decheng Capital LLC sold $60.7M worth of shares in ARMO BioSciences, Inc. in June 2018

Jul 08, 2018
Insider Transactions
Background Information
ARMO BioSciences, Inc. develops immunotherapy for the treatment of cancer, cardiovascular diseases, fibrosis, and inflammation. Its lead product candidate is AM0010 (pegilodecaki). The company was founded by Peter Van Vlasselaer, Martin Oft, and John B. Mumm on June 23, 2010 and is headquartered in Redwood, CA.